Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The C3a anaphylatoxin chemotactic receptor (C3AR1), commonly known as the C3a receptor (C3aR), is a rhodopsin-like G protein-coupled receptor (GPCR) that plays a pivotal role in the innate immune system. It is primarily activated by C3a, a pro-inflammatory anaphylatoxin generated during the complement activation cascade. C3aR is widely expressed on myeloid cells (such as mast cells, macrophages, and neutrophils) as well as non-myeloid cells in the central nervous system and peripheral tissues. Upon ligand binding, C3aR triggers intracellular signaling pathways, including Galpha-i and Galpha-12/13 activation, calcium mobilization, and beta-arrestin recruitment, which mediate chemotaxis, degranulation, and cytokine production.
C3aR signaling is heavily implicated in the pathogenesis of various inflammatory, cardiovascular, and neurodegenerative diseases, including asthma, ischemic stroke, diabetic nephropathy, and neuropathic pain. While acute activation of C3aR often exacerbates tissue damage and neuroinflammation, it can also exert protective, regenerative effects during subacute or chronic recovery phases, highlighting a complex, double-edged role. Therapeutic targeting of C3aR has focused on developing small-molecule antagonists, such as SB290157 and JR14a, to mitigate pathological inflammation. However, drug development has been challenged by the pharmacological complexity of existing ligands, some of which exhibit partial agonism or signaling bias, and no C3aR-targeted therapies have successfully transitioned to clinical trials to date.
Antagonist of the C3a receptor, blocking C3a-mediated signaling and chemotaxis; or agonist activating downstream G-protein and beta-arrestin pathways.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C3a anaphylatoxin chemotactic receptor (C3AR1).